Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter.

[1]  R. Weber,et al.  Anaplastic thyroid carcinoma: palliation or treatment? , 2011, Current opinion in otolaryngology & head and neck surgery.

[2]  M. Gonen,et al.  Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus , 2011, Journal of Translational Medicine.

[3]  S. Devesa,et al.  Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. , 2011, Thyroid : official journal of the American Thyroid Association.

[4]  Bonnie F. Sloane,et al.  Cathepsin B: a potential prognostic marker for inflammatory breast cancer , 2011, Journal of Translational Medicine.

[5]  J. Moley,et al.  Medullary, anaplastic, and metastatic cancers of the thyroid. , 2010, Seminars in oncology.

[6]  A. Melcher,et al.  The biology of the sodium iodide symporter and its potential for targeted gene delivery. , 2010, Current cancer drug targets.

[7]  J. Stritzker,et al.  Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent , 2009, Cancer Gene Therapy.

[8]  Y. Fong,et al.  Real‐time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV‐1h68 in an immunocompetent animal model , 2009, International journal of cancer.

[9]  Y. Fong,et al.  Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68 , 2009, Molecular Cancer Therapeutics.

[10]  R. Wong,et al.  Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  V. Rusch,et al.  Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. , 2008, Human gene therapy.

[12]  J. Shah,et al.  Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. , 2007, Surgery.

[13]  F. Marincola,et al.  Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. , 2007, Cancer research.

[14]  M. Vähä-Koskela,et al.  Oncolytic viruses in cancer therapy , 2007, Cancer Letters.

[15]  G. Brent,et al.  Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. , 2006, Endocrine-related cancer.

[16]  D. Lee,et al.  In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. , 2004, Thyroid : official journal of the American Thyroid Association.

[17]  D. Feller-Kopman,et al.  Central airway obstruction. , 2004, American journal of respiratory and critical care medicine.

[18]  J. Romijn,et al.  Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. , 2000, Thyroid : official journal of the American Thyroid Association.

[19]  M. Gnant,et al.  Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. , 1999, Journal of the National Cancer Institute.

[20]  T. Endo,et al.  Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. , 1997, Endocrinology.

[21]  B. Moss,et al.  Transient dominant selection of recombinant vaccinia viruses , 1990, Journal of virology.

[22]  S. Libutti,et al.  Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant , 2000, Cancer Gene Therapy.

[23]  F. Fenner.  Smallpox and its eradication , 1988 .